Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections

• Status: Unknown status
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This prospective controlled randomized open-label clinical trial is designed to determine the optimal eradication rate of rabeprazole based sequential-concommitant hybrid therapies for adults infected with Helicobacter pylori in Eastern Taiwan. Enrolled patients will receive 3, 5 or 7 days of pre-concommitant (sequential part) treatment with rabeprazole + amoxicillin, then 7 days of concommitant treatment with rabeprazole + amoxicillin + clarithromycin + metronidazole.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Buddhist Tzu Chi General Hospital
• Collaborator: Kaohsiung Medical University
• Treatments: Amoxicillin; Clarithromycin; Metronidazole; Rabeprazole

Criteria

Inclusion Criteria:

• Patient proved with infection of H. pylori in gastric mucosa (at least two of four tests positive)

Exclusion Criteria:

• woman in breast feeding or pregnancy.

• allergy to drugs used in study.

• previously treated for H. pylori.

• intolerance to fructose, lactose.

• patients with hematologic, brain or spinal disorders

• patients under 20 years old

• patients under aspirin or clopidogrel

• patients with history of gastric cancer or gastric resection operation.